News coverage about CytRx Corporation (NASDAQ:CYTR) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CytRx Corporation earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.0154717915683 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

CYTR has been the subject of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of CytRx Corporation in a research note on Wednesday, April 26th. ValuEngine raised shares of CytRx Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. CytRx Corporation has an average rating of “Hold” and an average target price of $2.50.

Shares of CytRx Corporation (CYTR) traded down 6.58% on Tuesday, reaching $0.64. 5,815,289 shares of the company traded hands. The firm has a 50-day moving average of $0.64 and a 200-day moving average of $0.52. The company’s market capitalization is $97.31 million. CytRx Corporation has a 52-week low of $0.36 and a 52-week high of $1.00.

CytRx Corporation (NASDAQ:CYTR) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.10) earnings per share for the quarter. On average, equities research analysts forecast that CytRx Corporation will post ($0.50) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/08/cytrx-corporation-cytr-earning-somewhat-favorable-press-coverage-study-finds.html.

CytRx Corporation Company Profile

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.

Insider Buying and Selling by Quarter for CytRx Corporation (NASDAQ:CYTR)

Receive News & Ratings for CytRx Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytRx Corporation and related companies with MarketBeat.com's FREE daily email newsletter.